Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US

Current Medical Research and Opinion
Sandra L Tunis, Michael E Minshall

Abstract

Stakeholders in the US and elsewhere are interested in country-specific and cohort-specific information with which to assess the long-term value of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes mellitus (T2DM) on oral anti-diabetes drugs (OADs). This study modeled the cost-effectiveness of SMBG at frequencies of once, twice, or three times per day for this population, and included those who had used SMBG in the prior year. Based on clinical findings of a longitudinal Kaiser Permanente study, a validated model was used to project 40-year clinical and economic outcomes for SMBG at (averages of) once, twice, or three times per day versus no SMBG. Baseline HbA1c (7.6%), age and gender represented the Kaiser study 'prevalent' SMBG users cohort. Unit costs came primarily from a 2003 published article; inflated to US$2006. Outcomes were discounted at 3% per annum, with sensitivity analyses on discount rates and time horizons. Analyses were conducted from a third-party payer perspective in the US, including only direct costs. Primary outcomes were differences in total costs, cumulative incidence of complications, quality-adjusted life years (QALYs); and incremental cost-effectiveness ratios (ICERs). For pati...Continue Reading

References

Dec 1, 1994·Acta Diabetologica·D B MuchmoreM Miller
Apr 1, 1996·Diabetes Research and Clinical Practice·A L CarringtonA J Boulton
Jun 8, 2000·Medical Care·T O Tengs, A Wallace
Aug 10, 2000·Medical Decision Making : an International Journal of the Society for Medical Decision Making·E F HalpernG S Gazelle
Apr 12, 2001·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·J Kantor, D J Margolis
Jul 29, 2003·Diabetes Care·Michael BrandleWilliam H Herman
Nov 14, 2003·Journal of Managed Care Pharmacy : JMCP·Kathleen A Fairman, Brenda R Motheral
Aug 25, 2004·Current Medical Research and Opinion·Andrew J PalmerGiatgen A Spinas
Aug 31, 2004·Diabetes Care·UNKNOWN American Diabetes Association Consensus Panel
Apr 13, 2006·JAMA : the Journal of the American Medical Association·Christopher D SaudekRita R Kalyani
May 20, 2006·Current Medical Research and Opinion·Andrew J PalmerAndrew J Karter
Jul 29, 2006·Diabetes Care·Andrew J KarterJoe V Selby
Aug 18, 2006·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·M SchüttUNKNOWN DPV Initiative
Mar 1, 2008·Diabetes Care·UNKNOWN American Diabetes Association
Apr 19, 2008·BMJ : British Medical Journal·Judit SimonUNKNOWN Diabetes Glycaemic Education and Monitoring Trial Group
Apr 26, 2008·Diabetes, Obesity & Metabolism·Anthony H Barnett
Nov 4, 2009·Journal of Diabetes Science and Technology·David C KlonoffAlison Okada Wollitzer

❮ Previous
Next ❯

Citations

Jan 1, 2010·Sensors·Eun-Hyung Yoo, Soo-Youn Lee
Feb 6, 2016·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Timothy S BaileyUNKNOWN American College of Endocrinology (ACE)
Nov 22, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Carlo B GiordaJesús Diago Cabezudo
Sep 23, 2016·Journal of Diabetes and Its Complications·Akiko NishimuraNobuya Inagaki
Feb 5, 2016·Journal of Diabetes Science and Technology·Stephanie J FondaRobert A Vigersky
Feb 4, 2011·The Analyst·Jeffrey T La BelleCurtiss B Cook

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.